ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport

• Verfasst von: Liu, Bin [VerfasserIn]
• Verfasst von: Azfar, Mujahid [VerfasserIn]
• Verfasst von: Legchenko, Ekaterina [VerfasserIn]
• Verfasst von: West, James A [VerfasserIn]
• Verfasst von: Martin, Shaun [VerfasserIn]
• Verfasst von: Van den Haute, Chris [VerfasserIn]
• Verfasst von: Baekelandt, Veerle [VerfasserIn]
• Verfasst von: Wharton, John [VerfasserIn]
• Verfasst von: Howard, Luke [VerfasserIn]
• Verfasst von: Wilkins, Martin R [VerfasserIn]
• Verfasst von: Vangheluwe, Peter [VerfasserIn]
• Verfasst von: Morrell, Nicholas W [VerfasserIn]
• Verfasst von: Upton, Paul D [VerfasserIn]
• Titel: ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport
• Verf.angabe: Bin Liu, Mujahid Azfar, Ekaterina Legchenko, James A West, Shaun Martin, Chris Van den Haute, Veerle Baekelandt, John Wharton, Luke Howard, Martin R Wilkins, Peter Vangheluwe, Nicholas W Morrell, Paul D Upton
• E-Jahr: 2024
• Jahr: May 2024
• Umfang: 13 S.
• Illustrationen: Illustrationen
• Fussnoten: Online veröffentlicht: 16. April 2024 ; Gesehen am 26.02.2025
• Titel Quelle: Enthalten in: Cardiovascular research
• Ort Quelle: Oxford : Oxford University Press, 1967
• Jahr Quelle: 2024
• Band/Heft Quelle: 120(2024), 7, Seite 756-768
• ISSN Quelle: 1755-3245
• DOI: doi:10.1093/cvr/cvae068
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1918624518

Abstract

Potential loss-of-function variants of ATP13A3, the gene encoding a P5B-type transport ATPase of undefined function, were recently identified in patients with pulmonary arterial hypertension (PAH). ATP13A3 is implicated in polyamine transport but its function has not been fully elucidated. In this study, we sought to determine the biological function of ATP13A3 in vascular endothelial cells (ECs) and how PAH-associated variants may contribute to disease pathogenesis.We studied the impact of ATP13A3 deficiency and overexpression in EC models [human pulmonary ECs, blood outgrowth ECs (BOECs), and human microvascular EC 1], including a PAH patient-derived BOEC line harbouring an ATP13A3 variant (LK726X). We also generated mice harbouring an Atp13a3 variant analogous to a human disease-associated variant to establish whether these mice develop PAH. ATP13A3 localized to the recycling endosomes of human ECs. Knockdown of ATP13A3 in ECs generally reduced the basal polyamine content and altered the expression of enzymes involved in polyamine metabolism. Conversely, overexpression of wild-type ATP13A3 increased polyamine uptake. Functionally, loss of ATP13A3 was associated with reduced EC proliferation, increased apoptosis in serum starvation, and increased monolayer permeability to thrombin. The assessment of five PAH-associated missense ATP13A3 variants (L675V, M850I, V855M, R858H, and L956P) confirmed loss-of-function phenotypes represented by impaired polyamine transport and dysregulated EC function. Furthermore, mice carrying a heterozygous germline Atp13a3 frameshift variant representing a human variant spontaneously developed a PAH phenotype, with increased pulmonary pressures, right ventricular remodelling, and muscularization of pulmonary vessels.We identify ATP13A3 as a polyamine transporter controlling polyamine homeostasis in ECs, a deficiency of which leads to EC dysfunction and predisposes to PAH. This suggests a need for targeted therapies to alleviate the imbalances in polyamine homeostasis and EC dysfunction in PAH.